AACR21 roundup: Arcus rolls out PhI data on adenosine blocker for CRC; Codiak's engineered exosome for IL-12 shows early promise
Arcus Biosciences’ adenosine blocker etrumadenant showed some benefit in extending patients’ lives as part of a Phase I/Ib trial in third …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
